RG
REGN icon

Redmile Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Redmile Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,000
Closed -$275K – 65
2013
Q4 		$275K Sell
1,000
-79,400
-99% -$22.8M 0.03% 52
2013
Q3 		$25.2M Buy
80,400
+19,400
+32% +$5.1M 3.79% 7
2013
Q2 		$13.7M Buy
+61,000
New +$14.2M 2.42% 16

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Redmile Group's REGN Position: Q1 2014 in Review

Redmile Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2014, closing a stake of 1,000 shares — an estimated $275K sold.

Redmile Group first reported a position in REGN in Q2 2013 and held it in 3 quarters. The position peaked at $25.2M in Q3 2013. 453 funds tracked by Wall St. Rank hold REGN as of Q1 2014.

  • Redmile Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Redmile Group sold 1,000 Regeneron Pharmaceuticals shares in Q1 2014, an estimated $275K.
  • Redmile Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Redmile Group's Regeneron Pharmaceuticals position peaked at $25.2M in Q3 2013.
  • 453 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2014.

Based on Redmile Group's 13F filing for Q1 2014, filed 15 May 2014.